| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Peter A. Ajibade | Q63928335 |
| Johannes Z Mbese | Q89976072 | ||
| Ayodele T Odularu | Q90469059 | ||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| Tyrosine kinase - Role and significance in Cancer. | Q24791430 | ||
| Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies | Q24810552 | ||
| Nutritional Aspects of Essential Trace Elements in Oral Health and Disease: An Extensive Review | Q26738956 | ||
| Challenges and strategies in anti-cancer nanomedicine development: An industry perspective | Q26748018 | ||
| Molecular Imaging of Biomarkers in Breast Cancer | Q26772870 | ||
| Peptide-Based Treatment: A Promising Cancer Therapy | Q26777032 | ||
| Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities | Q26828930 | ||
| Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role | Q26852086 | ||
| Is cancer a metabolic disease? | Q26852241 | ||
| Biomedical detection via macro- and nano-sensors fabricated with metallic and semiconducting oxides | Q27008543 | ||
| Nanomedicine therapeutic approaches to overcome cancer drug resistance | Q27011692 | ||
| Can nanomedicines kill cancer stem cells? | Q27022017 | ||
| The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs | Q28066801 | ||
| Imaging biomarker roadmap for cancer studies | Q30242020 | ||
| Biosensors: the new wave in cancer diagnosis | Q30447534 | ||
| Organometallic anticancer agents: cellular uptake and cytotoxicity studies on thiol derivatives of the antitumor agent molybdocene dichloride | Q30984981 | ||
| Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatme | Q33561588 | ||
| Smart electrospun nanofibers for controlled drug release: recent advances and new perspectives | Q33857874 | ||
| Far beyond the usual biomarkers in breast cancer: a review | Q33935217 | ||
| In vitro cytotoxicity of nanoparticles in mammalian germline stem cells | Q34025003 | ||
| The role of HER2 in cancer therapy and targeted drug delivery | Q34054213 | ||
| Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications | Q34223494 | ||
| The epidermal growth factor receptor family: biology driving targeted therapeutics | Q34692233 | ||
| Molybdenum enzymes in higher organisms | Q34812986 | ||
| Hydrophilic molybdenum oxide nanomaterials with controlled morphology and strong plasmonic absorption for photothermal ablation of cancer cells | Q35101450 | ||
| Nanotechnology for early cancer detection. | Q35727150 | ||
| Nanotechnology for cancer treatment. | Q35737878 | ||
| Tumor heterogeneity: mechanisms and bases for a reliable application of molecular marker design | Q35795835 | ||
| One-pot synthesis of PEGylated plasmonic MoO(3-x) hollow nanospheres for photoacoustic imaging guided chemo-photothermal combinational therapy of cancer. | Q35827369 | ||
| HER-2/neu diagnostics in breast cancer | Q35906255 | ||
| The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients | Q36153924 | ||
| Inflammatory Biomarkers, Comorbidity, and Neurocognition in Women With Newly Diagnosed Breast Cancer | Q36173493 | ||
| The 18-kDa Translocator Protein Inhibits Vascular Cell Adhesion Molecule-1 Expression via Inhibition of Mitochondrial Reactive Oxygen Species | Q36418830 | ||
| Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status | Q36458793 | ||
| Nanostructured molybdenum oxide-based antibacterial paint: effective growth inhibition of various pathogenic bacteria. | Q53500408 | ||
| Correlation of HER2 status between primary tumors and corresponding circulating tumor cells in advanced breast cancer patients. | Q54732957 | ||
| Sequence-dependent attack on peptides by photoactivated platinum anticancer complexes. | Q55322316 | ||
| Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis | Q57112840 | ||
| Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods | Q57797237 | ||
| Nanoparticle-Mediated Combination Therapy: Two-in-One Approach for Cancer | Q57808219 | ||
| Comparative Photothermal Performance among Various Sub-Stoichiometric 2D Oxygen-Deficient Molybdenum Oxide Nanoflakes and In Vivo Toxicity | Q58922503 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Effect of dietary molybdenum on esophageal carcinogenesis in rats induced by N-methyl-N-benzylnitrosamine | Q68737216 | ||
| Lung tumor induction by inhalation exposure to molybdenum trioxide in rats and mice | Q77663765 | ||
| Nail molybdenum and zinc contents in populations with low and moderate incidence of esophageal cancer | Q81547060 | ||
| Nanotechnology and drug resistance | Q86621880 | ||
| Selectivity and sensitivity of molybdenum oxide-polycaprolactone nanofiber composites on skin cancer: Preliminary in-vitro and in-vivo implications | Q89080155 | ||
| Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 | Q90903275 | ||
| Portable detection of serum HER-2 in breast cancer by a pressure-based platform | Q91556766 | ||
| Nanostructured materials for applications in drug delivery and tissue engineering | Q36807625 | ||
| The Metabolism, Analysis, and Targeting of Steroid Hormones in Breast and Prostate Cancer | Q36880048 | ||
| HER2+ breast cancer: review of biologic relevance and optimal use of diagnostic tools | Q37061603 | ||
| Evaluation of HER2/neu oncoprotein in serum & tissue samples of women with breast cancer | Q37367705 | ||
| HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment | Q37580586 | ||
| Nanomaterials for cancer therapy and imaging | Q37601740 | ||
| Noble metal nanoparticles for biosensing applications | Q37996011 | ||
| Metallocenes as Target Specific Drugs for Cancer Treatment | Q38062521 | ||
| Targeted delivery of platinum-based anticancer complexes | Q38080318 | ||
| Role of integrated cancer nanomedicine in overcoming drug resistance. | Q38123622 | ||
| Rationally designed nanovehicles to overcome cancer chemoresistance | Q38129698 | ||
| Nanotechnology approaches for personalized treatment of multidrug resistant cancers | Q38152145 | ||
| Organometallic compounds in cancer therapy: past lessons and future directions. | Q38244846 | ||
| Nanotechnology: an effective tool for enhancing bioavailability and bioactivity of phytomedicine | Q38245647 | ||
| CCR 20th Anniversary Commentary: Prospects and Challenges of Therapeutic Nanoparticles in Cancer | Q38608825 | ||
| Metal complexes in cancer therapy - an update from drug design perspective | Q38692975 | ||
| Cytotoxicity studies of water soluble coordination compounds with a [Mo2O2S2](2+) core. | Q38790720 | ||
| Addressing intra-tumoral heterogeneity and therapy resistance | Q38823179 | ||
| Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer? | Q38933699 | ||
| Antimicrobial Properties of Graphene Oxide Nanosheets: Why Size Matters. | Q38993816 | ||
| Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). | Q39161262 | ||
| The syntheses and characterizations of molybdenum(VI) complexes with catechol and 2,3-dihydroxynaphthalene, and the structure-effect relationship in their in vitro anticancer activities | Q39332426 | ||
| The nanomedicine revolution: part 2: current and future clinical applications. | Q39527453 | ||
| Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. | Q39608822 | ||
| Evidence for Treatment-by-Biomarker interaction for FDA-approved Oncology Drugs with Required Pharmacogenomic Biomarker Testing | Q40100583 | ||
| HER2-positive circulating tumor cells indicate poor clinical outcome in stage I to III breast cancer patients | Q40341072 | ||
| Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors | Q42373834 | ||
| Estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 expression in breast cancer FNA cell blocks and paired histologic specimens: A large retrospective study | Q46387180 | ||
| Toxicity of nano molybdenum trioxide toward invasive breast cancer cells | Q46946999 | ||
| Construction and Potential Applications of Biosensors for Proteins in Clinical Laboratory Diagnosis | Q47281748 | ||
| Biomarkers and Imaging of Breast Cancer | Q47428221 | ||
| Targeting Strategies for the Combination Treatment of Cancer Using Drug Delivery Systems | Q47440128 | ||
| Molybdenum anode: a novel electrode for enhanced power generation in microbial fuel cells, identified via extensive screening of metal electrodes | Q49581218 | ||
| Highly stable molybdenum dioxide nanoparticles with strong plasmon resonance are promising in photothermal cancer therapy | Q49917789 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 6416198 | |
| P577 | publication date | 2019-09-10 | |
| P1433 | published in | Bioinorganic Chemistry and Applications | Q15757987 |
| P1476 | title | Impact of Molybdenum Compounds as Anticancer Agents | |
| P478 | volume | 2019 |
Search more.